The three patient groups otherwise had similar clinical and biochemical characteristics, with similar plasma C-reactive protein, NT-proBNP, CML, LMWF, and soluble RAGE levels, and received similar therapies, apart from anti-diabetic therapies. The gene discussed is NPPB; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.